艾司西酞普兰与帕罗西汀治疗脑卒中后抑郁有效性和安全性的Meta分析

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the effect and safety of Escitalopram and Paroxetine in the treatment of post-stroke depression (PSD). Methods The randomized controlled trials (RCTs) of Escitalopram and Paroxetine for treating PSD were retrieved in PubMed, Cochrane Library, Wanfang database, CBM, CNKI, Google Scholar, Baidu Scholar published from the establishment of the database to November 2019 by computer. After extracting the data and evaluating the quality, the RevMan 5.3 software was used to conduct Meta-analysis on the data. Results Finally 9 RCTs were included, involving 765 patients. The results of Meta-analysis showed that the Hamilton depression rating scale(HAMD) score in the experimental group decreased more than that in the control group after 1 week of treatment, and the difference was statistically significant (SMD=-0.83, 95%CI[-1.06, -0.60], Z=7.05, P＜0.000 01). After 2, 4, 6 or 8 weeks of treatment, there were no significant differences in HAMD scores between the two groups (P＞0.05). There was no statistically significant difference in the effective rate between the two groups after 6 or 8 weeks of treatment (RR=1.03, 95%CI[0.98, 1.09], Z=1.12, P=0.26). The incidence rates of dry mouth, nausea, headache, and constipation in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion Escitalopram has the same effect as Paroxetine in the treatment of PSD, but Escitalopram has a faster onset.

Key words： Escitalopram Paroxetine Post-stroke depression Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Zhi-rong
	LU Jin-xin
	WAN Fang
	YIN Yan-wei

Cite this article:

FANG Zhi-rong,LU Jin-xin,WAN Fang, et al. Meta-analysis of effect and safety of Escitalopram and Paroxetine in the treatment of post-stroke depression[J]. 中国当代医药, 2020, 27(28): 17-20转32.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I28/17

[1]	全国第四届脑血管病学术会议.各类脑血管疾病诊断要点[J].中华神经科杂志，1996，（6）：60-61.
[2]	中华医精神病学分会.中国精神障碍分类与诊断标准第3版（CCMD3）[M].济南：山东科学技术出版社，2001：87-89.
[3]	梁战妹.艾司西酞普兰与帕罗西汀治疗卒中后抑郁效果及安全性对比分析[J].北方医学，2018，15（7）：147.
[4]	祝云龙，张治华，徐建刚.艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的对照研究[J].中国药业，2012，21（19）：75-76.
[5]	李新峰.艾司西酞普兰治疗脑卒中后抑郁焦虑共病的对照研究[J].中国现代药物应用，2014，8（14）：151-152.
[6]	白树新，王德斌，李广玉，等.草酸艾司西酞普兰与盐酸帕罗西汀治疗脑卒中后抑郁的临床对照研究[J].河北医药，2013，35（2）：230-231.
[7]	吴盛各，徐建，郭华贵.艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的对照研究[J].黑龙江医学，2013，37（1）：8-10.
[8]	李国宏.艾司西酞普兰治疗缺血性脑卒中后抑郁的效果[J].中国临床保健杂志，2019，22（1）：100-104.
[9]	武文珺，王怀海，彭正午，等.4 种SSRI 类抗抑郁药物治疗卒中后抑郁疗效及对生活质量的影响[J].神经疾病怀精神卫生，2013，13（1）：16-19.
[10]	孙同.草酸艾司西酞普兰治疗脑卒中后抑郁的疗效观察[J].中国实用神经疾病杂志，2016，19（11）：127-128.
[11]	罗儒献，蒋陆萍，刘星星，等.艾司西酞普兰治疗脑卒中后抑郁的对照研究[J].海南医学，2014，25（10）：1487-1488.
[12]	谷岩，姜涛，郭建兵，等.艾司西酞普兰与帕罗西汀治疗老年性抑郁症对照研究[J].中国心理卫生杂志，2010，24（6）：445-449.
[13]	Bilge C，Kocer E，Kocer A，et al.Depression and functional outcome after stroke the effect of antidepressant therapy on functional recovery[J].Eur J Phys Rehabil Med，2008，44（1）：13-18.
[14]	Paolucci S，Grasso MG，Antonucci G，et al.One-year follow-up instroke patients discharged from rehabilitation hospital[J].Cerebrovasc Dis，2000，10（1）：25-32.
[15]	Feigin VL，Barker-Collo S，Krishnamurthi R，et al.Epidemiology of ischaemic stroke and traumatic brain injury[J].Best Pract Res Clin Anaesthesiol，2010，24（4）：485-494.
[16]	Williams LS，Ghose SS，Swindle RW.Depression and other mental health diagnoses increase mortality risk after ischemic stroke[J].Am J Psychiatr，2004，161（6）：1090-1095.
[17]	Gao HQ，Zhu HY，Zhang YQ，et al.Reduction of cerebrospinal fluid and plasma serotonin in patients with poststroke depression：A preliminary report[J].Clin Invest Med，2008，31（6）：E351-E356.
[18]	Andersen G，Vestergaard K，Ingemann-Nielsen M，et al.Risk factors for post-stroke depression[J].Acta Psychiatr Scand，1995，92（3）：193-198.